Literature DB >> 3878759

The anticholinesterase activity of mefloquine.

L Y Lim, M L Go.   

Abstract

The characteristics of the inhibition of electric eel acetylcholinesterase (AChE) and horse serum butyrylcholinesterase (BChE) by the antimalarial agents mefloquine, chloroquine, amodiaquine and amopyroquine were determined. The antimalarials were found to be non-competitive inhibitors of both AChE and BChE. In both enzyme systems, inhibitory potencies were in the order amodiaquine greater than amopyroquine greater than chloroquine greater than mefloquine. The low inhibitory potency of mefloquine may account in part for the appearance of gastrointestinal and central nervous system disturbances only at high doses of the drug.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3878759     DOI： 10.1111/j.1440-1681.1985.tb00904.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN： 0305-1870            Impact factor:   2.557


  8 in total

1.  Investigation of the in vitro gender-specific partitioning of mefloquine in malarial infected red blood cells and plasma.

Authors:  Nongluk Seethorn; Walther H Wernsdorfer; Harald Noedl; Juntra Karbwang; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2013-09-03       Impact factor: 2.345

2.  Utility of alkylaminoquinolinyl methanols as new antimalarial drugs.

Authors:  G S Dow; T N Heady; A K Bhattacharjee; D Caridha; L Gerena; M Gettayacamin; C A Lanteri; N Obaldia; N Roncal; T Shearer; P L Smith; A Tungtaeng; L Wolf; M Cabezas; D Yourick; K S Smith
Journal:  Antimicrob Agents Chemother       Date:  2006-09-11       Impact factor: 5.191

3.  Anti-malaria drug mefloquine induces motor learning deficits in humans.

Authors:  Thomas A van Essen; Ruben S van der Giessen; Sebastiaan K E Koekkoek; Frans Vanderwerf; Chris I De Zeeuw; Perry J J van Genderen; David Overbosch; Marcel T G de Jeu
Journal:  Front Neurosci       Date:  2010-11-19       Impact factor: 4.677

4.  Mefloquine induces dose-related neurological effects in a rat model.

Authors:  G Dow; R Bauman; D Caridha; M Cabezas; F Du; R Gomez-Lobo; M Park; K Smith; K Cannard
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

5.  Drug repurposing applied: Activity of the anti-malarial mefloquine against Echinococcus multilocularis.

Authors:  Britta Lundström-Stadelmann; Reto Rufener; Andrew Hemphill
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2020-07-02       Impact factor: 4.077

6.  Gender-specific distribution of mefloquine in the blood following the administration of therapeutic doses.

Authors:  Walther H Wernsdorfer; Harald Noedl; Pamela Rendi-Wagner; Herwig Kollaritsch; Gerhard Wiedermann; Andrea Mikolasek; Juntra Karbwang; Kesara Na-Bangchang
Journal:  Malar J       Date:  2013-12-09       Impact factor: 2.979

7.  Gap junction blockers: a potential approach to attenuate morphine withdrawal symptoms.

Authors:  Sabah Moradi; Mohammad Charkhpour; Hamed Ghavimi; Rasoul Motahari; Majid Ghaderi; Kambiz Hassanzadeh
Journal:  J Biomed Sci       Date:  2013-10-21       Impact factor: 8.410

8.  Activity of mefloquine and mefloquine derivatives against Echinococcus multilocularis.

Authors:  Reto Rufener; Dominic Ritler; Jana Zielinski; Luca Dick; Emerson Teixeira da Silva; Adriele da Silva Araujo; Deborah Elisabeth Joekel; David Czock; Christine Goepfert; Adriana Marques Moraes; Marcus Vinicius Nora de Souza; Joachim Müller; Meike Mevissen; Andrew Hemphill; Britta Lundström-Stadelmann
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-06-15       Impact factor: 4.077
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.